Literature DB >> 7643626

Expression of FLT3 receptor and FLT3-ligand in human leukemia-lymphoma cell lines.

G Meierhoff1, U Dehmel, H J Gruss, O Rosnet, D Birnbaum, H Quentmeier, W Dirks, H G Drexler.   

Abstract

The FLT3 gene encodes a receptor tyrosine kinase that is closely related to two well-known receptors, KIT and FMS, that regulate with their respective ligands, stem cell factor (SCF) and macrophage colony-stimulating factor (M-CSF), proliferation and differentiation of hematopoietic cells. The ligand for FLT3, FL, is active in both soluble and membrane-bound forms. We examined expression of FL and FLT3 mRNA in a panel of some 110 continuous human leukemia-lymphoma cell lines from all major hematopoietic cell lineages by Northern blot analysis. FLT3 mRNA is expressed primarily in pre-B cell lines, myeloid and monocytic cell lines whereas FL mRNA was detected in most cell lines from all cell lineages. Analysis of FLT3 receptor protein expression examined with a specific anti-FLT3 monoclonal antibody and flow cytometry in 17 cell lines confirmed the results obtained at the mRNA level. Forty of 110 cell lines displayed both receptor and ligand mRNA suggesting a possible autocrine or intracrine stimulation. In normal hematopoietic cells expression of FLT3 was reported to be associated with CD34 positivity, a cell surface marker of immature and precursor cells. No correlation between FLT3 and CD34 expression was found in the cell lines analyzed. These studies served to illustrate further the importance of the FL-FLT3 ligand-receptor system in the regulation of hematopoietic cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7643626

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  19 in total

1.  FLT3 ligand plasma levels in acute myeloid leukemia.

Authors:  Pierre Peterlin; Joelle Gaschet; Thierry Guillaume; Alice Garnier; Marion Eveillard; Amandine Le Bourgeois; Michel Cherel; Camille Debord; Yannick Le Bris; Olivier Theisen; Béatrice Mahé; Viviane Dubruille; Catherine Godon; Nelly Robillard; Soraya Wuilleme; Cyrille Touzeau; Thomas Gastinne; Nicolas Blin; Anne Lok; Antoine Bonnet; Steven Le Gouill; Philippe Moreau; Marie-C Béné; Patrice Chevallier
Journal:  Haematologica       Date:  2019-01-10       Impact factor: 9.941

2.  Treatment of FLT3-ITD acute myeloid leukemia.

Authors:  Amir T Fathi; Yi-Bin Chen
Journal:  Am J Blood Res       Date:  2011-09-09

3.  Internal tandem duplications of the FLT3 gene are present in leukemia stem cells.

Authors:  Mark Levis; Kathleen M Murphy; Rosalyn Pham; Kyu-Tae Kim; Adam Stine; Li Li; Ian McNiece; B Douglas Smith; Donald Small
Journal:  Blood       Date:  2005-03-29       Impact factor: 22.113

Review 4.  FLT3 tyrosine kinase inhibitors.

Authors:  Mark Levis; Donald Small
Journal:  Int J Hematol       Date:  2005-08       Impact factor: 2.490

5.  Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia.

Authors:  Paul Milne; Charlotte Wilhelm-Benartzi; Michael R Grunwald; Venetia Bigley; Richard Dillon; Sylvie D Freeman; Kathleen Gallagher; Amy Publicover; Sarah Pagan; Helen Marr; Gail L Jones; Anne M Dickinson; Angela Grech; Alan K Burnett; Nigel H Russell; Mark Levis; Steven Knapper; Matthew Collin
Journal:  Blood Adv       Date:  2019-10-22

6.  FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations.

Authors:  Amir T Fathi; Bruce A Chabner
Journal:  Oncologist       Date:  2011-07-17

Review 7.  Bench to bedside targeting of FLT3 in acute leukemia.

Authors:  Keith W Pratz; Mark J Levis
Journal:  Curr Drug Targets       Date:  2010-07       Impact factor: 3.465

8.  Development and Characterization of FLT3-Specific Curcumin-Loaded Polymeric Micelles as a Drug Delivery System for Treating FLT3-Overexpressing Leukemic Cells.

Authors:  Singkome Tima; Siriporn Okonogi; Chadarat Ampasavate; Chad Pickens; Cory Berkland; Songyot Anuchapreeda
Journal:  J Pharm Sci       Date:  2016-10-14       Impact factor: 3.534

Review 9.  Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens.

Authors:  Keith Pratz; Mark Levis
Journal:  Leuk Lymphoma       Date:  2008-05

10.  Detection of FLT3 oncogene mutations in acute myeloid leukemia using conformation sensitive gel electrophoresis.

Authors:  Mamdooh Gari; Adel Abuzenadah; Adeel Chaudhary; Mohammed Al-Qahtani; Huda Banni; Waseem Ahmad; Fatin Al-Sayes; Sahira Lary; Ghazi Damanhouri
Journal:  Int J Mol Sci       Date:  2008-11-11       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.